By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AMAG Pharmaceuticals, Inc. 

1100 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 617-498–3300 Fax: 617-499-3361


SEARCH JOBS

Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.

AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.


Key Statistics


Email: contactus@amagpharma.com
Ownership: Public

Web Site: AMAG
Employees: 51-200
Symbol: AMAG
 




Segment
Pharmaceuticals





Company News
AMAG (AMAG) to Hire 150 New Sales Reps to Support New Drug Intrarosa 2/16/2017 5:50:28 AM
AMAG (AMAG) And EndoCeutics Enter Into An Exclusive U.S. License Agreement For Intrarosa (Prasterone) 2/14/2017 11:22:44 AM
AMAG (AMAG) Reports Fourth Quarter And Full Year 2016 Financial Results 2/14/2017 11:20:07 AM
AMAG (AMAG) To Host Fourth Quarter And Full Year 2016 Financial Results Conference Call And Webcast On Tuesday, February 14, 2017 At 8:00 A.M. ET 2/7/2017 10:44:21 AM
AMAG (AMAG) Announces Closing Of Exclusive Licensing Agreement For North American Rights To Rekynda (Bremelanotide) 2/3/2017 7:19:25 AM
Palatin Tech (PTN) Announces Closing Of License Agreement With AMAG (AMAG) For North American Rights To Rekynda 2/3/2017 6:58:11 AM
AMAG (AMAG) Announces Positive Topline Results From Definitive Pharmacokinetic Study For Makena Subcutaneous Administration 2/2/2017 10:42:38 AM
AMAG (AMAG) Provides Financial And Business Update 1/9/2017 7:40:03 AM
AMAG (AMAG), Palatin Tech (PTN) Strike $440 Million Female Sexual Disorder Pact 1/9/2017 6:38:37 AM
AMAG (AMAG) Announces Appointment Of Brian Kelley To Board Of Directors 12/21/2016 9:12:50 AM
12345678910...
//-->